Skip to main content



Coffee with milk may have an anti-inflammatory effect

Jan 30, 2023

Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study from the University of Copenhagen. A combination of proteins and antioxidants doubles the anti-inflammatory properties.

Read Article

Pathogenic Impact of microRNA Cotargeting in Lupus

Jan 27, 2023

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple

Read Article
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

  1. "Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs

Read Article

VEXAS may be more common than expected

Jan 25, 2023

A great study of a recently described rheumatologic/hematologic disorder VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome recently appeared in JAMA, describing the frequency and presentations of UBA1 variant. 

Read Article

New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients

Jan 17, 2023

Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the American College of Rheumatology (ACR), though the timing for their administration and dosing of antirheumatic drugs may need adjustment in some cases.

Read Article

Holes in TH17 cells release IL-1α on NLRP3 activation

Jan 10, 2023

Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and an international research team discovered. They have thus revealed several previously

Read Article

2022 Rheumatology Year in Review

Jan 05, 2023

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article

Lubricin as a Treatment Target in Gout?

Jan 04, 2023

Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.

Gout is indeed one of the earliest known diseases, first

Read Article

Best of 2022: New Updated GRAPPA Psoriatic Arthritis Recommendations

Dec 26, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
Lungs ILD

Best of 2022: Approach to ILD in Myositis Syndromes

Dec 19, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article
lupus SLE

CXCL5 Therapy in Lupus?

Dec 14, 2022

 A new study has shown that restoring the balance of a protein in blood may be a promising treatment option for systemic lupus erythematosus.

Read Article

Inflammatory Arthritis and Hidradenitis Suppurativa

Dec 09, 2022

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or 

Read Article

The Top 10 Research Priorities in Psoriatic Arthritis

Dec 06, 2022

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA

Read Article
COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

Nov 14, 2022

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
Do you know the 3 types of Y. Pestis plague? @AdamJBrownMD reviews the Bubonic, Pneumonic, and Septicemia plagues at #ACR22 @RheumNow. Most recently, there was an outbreak of Pneumonic plague in Madagascar in the 2010s!

Proposed Cancer Screening for Inflammatory Myositis Patients

Nov 12, 2022

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this

Read Article

Anifrolumab shows long-term promise in patients with lupus

Nov 12, 2022

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from

Read Article
infection pneumonia

Opportunistic Infections with JAK inhibitors in RA

Nov 07, 2022

Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials,

Read Article
RheumNow Podcast square

Women with Rheumatic Disease (11.4.2022)

Nov 04, 2022

Dr. Jack Cush reviews the news and journal articles from this past week on  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

  1. Population study shows among vaccinated gout pts, COVID breakthrough

Read Article
Efficacy of Shingrix Vaccine lasts for 10 yrs. Shingrix was approved in 2017 based on 2 Lg RCTs showing 6 yr. protective efficacy of 97% (ages>50) * 91% (age >70). Long-term F/U shows 81.6% effectfor mean of 9.6 (±0.3) years post-vaccination
RheumNow Podcast square

ACR Award Winners (10.21.2022)

Oct 21, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

  1. Vaccination Cut Long COVID Risk for Rheum Patients Patients with

Read Article

Prevotella Immune Response in Both Pre-Clinical & Established RA

EurekAlert! and Jack Cush
Oct 19, 2022

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

Read Article

CRTAC1- a Novel Biomarker for Osteoarthritis

Oct 17, 2022

Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.

Read Article